No connection

Search Results

Corporate Score 42 Bullish

Seaport Therapeutics Prices Upsized IPO at $18 Per Share

Apr 30, 2026 23:27 UTC
Seaport Therapeutics
Short term

Clinical-stage biotech firm Seaport Therapeutics has raised approximately $255 million in its initial public offering. The offering was upsized and priced at the top of its expected range.

  • Raised nearly $255 million in US IPO
  • Shares priced at $18, the top of the $16-$18 range
  • Offering upsized to 14.6 million shares from 11.8 million
  • Funds to support neuro-psychiatry drug development

Seaport Therapeutics Inc., a biotechnology company specializing in the development of treatments for anxiety and depression, has successfully completed an upsized initial public offering (IPO) in the United States. The company raised nearly $255 million, signaling strong investor appetite for its neuro-psychiatry pipeline. The offering was priced at $18 per share, representing the maximum end of the previously marketed range of $16 to $18. To meet investor demand, Seaport increased the number of shares sold to 14.6 million, a significant increase from the 11.8 million shares originally indicated in its regulatory filings. This capital infusion provides the clinical-stage firm with substantial runway to advance its drug candidates through the development process. The successful pricing at the top of the range reflects positive market sentiment toward the company's specific focus on mental health therapeutics.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Share this article

Related Articles

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Home
Terminal
AI Chat
Markets
Profile